Caisse Des Depots ET Consignations Purchases New Shares in Harrow, Inc. (NASDAQ:HROW)

Caisse Des Depots ET Consignations acquired a new position in Harrow, Inc. (NASDAQ:HROW) during the fourth quarter, according to the company in its most recent filing with the SEC. The fund acquired 23,785 shares of the company’s stock, valued at approximately $798,000. Caisse Des Depots ET Consignations owned approximately 0.07% of Harrow at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Quest Partners LLC acquired a new position in shares of Harrow in the 3rd quarter worth approximately $29,000. AlphaQuest LLC lifted its stake in Harrow by 452.8% during the fourth quarter. AlphaQuest LLC now owns 3,527 shares of the company’s stock worth $118,000 after purchasing an additional 2,889 shares during the last quarter. KLP Kapitalforvaltning AS acquired a new position in Harrow in the fourth quarter worth $235,000. China Universal Asset Management Co. Ltd. increased its stake in Harrow by 10.7% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 7,552 shares of the company’s stock valued at $253,000 after purchasing an additional 727 shares during the last quarter. Finally, Virtu Financial LLC acquired a new stake in shares of Harrow during the third quarter worth $271,000. Institutional investors and hedge funds own 72.76% of the company’s stock.

Harrow Trading Up 0.8 %

Shares of HROW opened at $27.87 on Friday. The company has a debt-to-equity ratio of 3.23, a quick ratio of 1.44 and a current ratio of 1.55. The company has a market cap of $992.59 million, a price-to-earnings ratio of -29.65 and a beta of 0.69. The stock has a fifty day moving average price of $29.05 and a two-hundred day moving average price of $38.10. Harrow, Inc. has a 52-week low of $9.86 and a 52-week high of $59.23.

Harrow (NASDAQ:HROW) last issued its earnings results on Thursday, March 27th. The company reported $0.25 EPS for the quarter, beating the consensus estimate of $0.11 by $0.14. Harrow had a negative net margin of 19.75% and a negative return on equity of 45.57%. Analysts predict that Harrow, Inc. will post -0.53 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the stock. HC Wainwright reiterated a “buy” rating and issued a $57.00 price objective on shares of Harrow in a research report on Tuesday, March 18th. B. Riley cut their price target on Harrow from $73.00 to $69.00 and set a “buy” rating on the stock in a report on Wednesday, December 4th.

About Harrow

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.